We are a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body’s own T cells to generate a specific, potent and durable immune response that mimics natural biology. Our mission is to create therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. Currently, we have two product candidates in human trials: NEXI-001 in acute myeloid leukemia, or AML, and NEXI-002 in multiple myeloma, or MM.

The backbone of our approach is our proprietary Artificial Immune Modulation, or AIM^TM, nanoparticle technology platform. The AIM technology enables us to construct nanoparticles that function as synthetic dendritic cells capable of directing a specific T cell-mediated immune response. Like natural dendritic cells, the AIM nanoparticles employ natural signaling proteins to deliver specific instructions to specific T cells directing a desired immune response. 

(Note: NexImmune priced its upsized IPO on Feb. 11, 2021, by selling 6.47 million shares, up from 5.88 million, at $17, the top of the range, to raise  $109.99 million. The deal’s size was increased by 16.9 percent at pricing. The company had just upsized its IPO in an S-1/A filing on Feb. 11 to 5.88 million shares, up from 4.69 million initially, and kept the price range at $15 to $17.)